Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empagliflozin as an Adjunctive Strategy for Treating Bipolar Depression in Patients With Insulin Resistance: A Proof-of-Concept Study (EMPA-BD)

NCT07472920 is registered in ClinicalTrials.gov with University of Sao Paulo as lead sponsor.

NCT NCT07472920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07472920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empagliflozin as an Adjunctive Strategy for Treating Bipolar Depression in Patients With Insulin Resistance: A Proof-of-Concept Study (EMPA-BD)
Lead sponsor
University of Sao Paulo
Phase
Not applicable
Overall status
Not yet recruiting
Start date
March 9, 2026
Completion date
December 31, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar depression, bipolar disorder, insulin resistance